Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis

A systematic search of the PubMed, Cochrane, Embase, and Web of Science databases was conducted to investigate the risk of urinary bladder cancer (BC) in patients with inflammatory bowel disease (IBD). We identified 168 articles, of which 11 met the inclusion and exclusion criteria. Our analysis inc...

Full description

Bibliographic Details
Main Authors: Zhihua Geng, Qing Geng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Surgery
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2021.636791/full
id doaj-979dde7c32f547b8a75c118bd84d1a33
record_format Article
spelling doaj-979dde7c32f547b8a75c118bd84d1a332021-05-26T12:10:47ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2021-05-01810.3389/fsurg.2021.636791636791Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-AnalysisZhihua Geng0Qing Geng1Department of Orthopedics of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, ChinaA systematic search of the PubMed, Cochrane, Embase, and Web of Science databases was conducted to investigate the risk of urinary bladder cancer (BC) in patients with inflammatory bowel disease (IBD). We identified 168 articles, of which 11 met the inclusion and exclusion criteria. Our analysis included 165,176 patients with IBD, 491 of whom had BC. Overall, the pooled standardized incidence ratio (SIR) was 0.99 (95% CI: 0.87–1.12; I2 = 0%). Further subgroup analysis showed that BC risk was neither statistically higher for Crohn's disease (CD) (SIR: 1.19; 95% CI: 0.94–1.44; I2 = 0%) nor for patients with ulcerative colitis (UC) (SIR: 0.92; 95% CI: 0.77–1.06; I2 = 0%). In the analysis of two case-control studies providing data on BC in UC and CD combined, IBD patients seemed to have a higher risk of BC than non-IBD patients (relative risk: 1.25; 95% CI: 0.77–2.03; I2 = 37.5%). Although the overall risk of BC was not significantly increased among patients with IBD, there was a weak trend for the risk to be elevated in CD patients, indicating marginal significance. These findings may primarily be explained by the opposite effects of smoking on CD and UC as well as the immunosuppressive drugs these patients often take.https://www.frontiersin.org/articles/10.3389/fsurg.2021.636791/fullbladder cancerCrohn's diseaseinflammatory bowel diseasesulcerative colitismeta-analysis
collection DOAJ
language English
format Article
sources DOAJ
author Zhihua Geng
Qing Geng
spellingShingle Zhihua Geng
Qing Geng
Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
Frontiers in Surgery
bladder cancer
Crohn's disease
inflammatory bowel diseases
ulcerative colitis
meta-analysis
author_facet Zhihua Geng
Qing Geng
author_sort Zhihua Geng
title Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
title_short Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
title_full Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
title_fullStr Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
title_full_unstemmed Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
title_sort risk of urinary bladder cancer in patients with inflammatory bowel diseases: a meta-analysis
publisher Frontiers Media S.A.
series Frontiers in Surgery
issn 2296-875X
publishDate 2021-05-01
description A systematic search of the PubMed, Cochrane, Embase, and Web of Science databases was conducted to investigate the risk of urinary bladder cancer (BC) in patients with inflammatory bowel disease (IBD). We identified 168 articles, of which 11 met the inclusion and exclusion criteria. Our analysis included 165,176 patients with IBD, 491 of whom had BC. Overall, the pooled standardized incidence ratio (SIR) was 0.99 (95% CI: 0.87–1.12; I2 = 0%). Further subgroup analysis showed that BC risk was neither statistically higher for Crohn's disease (CD) (SIR: 1.19; 95% CI: 0.94–1.44; I2 = 0%) nor for patients with ulcerative colitis (UC) (SIR: 0.92; 95% CI: 0.77–1.06; I2 = 0%). In the analysis of two case-control studies providing data on BC in UC and CD combined, IBD patients seemed to have a higher risk of BC than non-IBD patients (relative risk: 1.25; 95% CI: 0.77–2.03; I2 = 37.5%). Although the overall risk of BC was not significantly increased among patients with IBD, there was a weak trend for the risk to be elevated in CD patients, indicating marginal significance. These findings may primarily be explained by the opposite effects of smoking on CD and UC as well as the immunosuppressive drugs these patients often take.
topic bladder cancer
Crohn's disease
inflammatory bowel diseases
ulcerative colitis
meta-analysis
url https://www.frontiersin.org/articles/10.3389/fsurg.2021.636791/full
work_keys_str_mv AT zhihuageng riskofurinarybladdercancerinpatientswithinflammatoryboweldiseasesametaanalysis
AT qinggeng riskofurinarybladdercancerinpatientswithinflammatoryboweldiseasesametaanalysis
_version_ 1721426329337856000